Restart Life Secures Strategic Production Partner

Rhea-AI Summary

Restart Life Sciences Corp. (NMLSD) has secured a strategic production partnership with a Canadian co-packer for manufacturing their Brain Balls product line. The co-packer, known for healthy cereals, will handle raw ingredients, packaging, and shipping from their British Columbia facility.

This partnership follows the December 13, 2024 joint venture with Brain Balls Inc. to develop health-focused products targeting cognitive performance and brain health. The company also completed a debt settlement of $118,476.75 by issuing 1,579,689 units at $0.075 per unit, each including one common share and one warrant exercisable at $0.10 for 12 months.

Additionally, Restart Life granted 1,830,000 stock options and 3,095,000 RSUs to officers, directors, and consultants, exercisable at $0.10 per share with a two-year term.

Positive

• Strategic production partnership secured with established Canadian health food co-packer
• Manufacturing facility ready for Brain Balls production in British Columbia
• Debt settlement completed, reducing company liabilities by $118,476.75

Negative

• Dilution of shareholder value through debt settlement share issuance
• Additional dilution from 1.83M stock options and 3.095M RSUs granted

Vancouver, British Columbia--(Newsfile Corp. - February 19, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD) ("Restart Life" or the "Company") is pleased to announce that the Company has secured a strategic production partnership with a Canadian co-packer. This new strategic partnership follows the press release dated December 13, 2024, where Restart Life and Brain Balls Inc. formed a Joint Venture to bring health-focused products to market, targeting cognitive performance, mental clarity, and overall brain health.

With this agreement, the co-packer, a recognized leader in the health food industry, will serve as the official production partner for the Brain Balls and subsequent product lines. The co-packer operates a fully equipped production facility in British Columbia, Canada, which will be utilized to handle raw ingredients, package and ship, ensuring the highest quality standards for consumers.

The co-packer, known for its flagship branded healthy cereals, has demonstrated a proven track record of success in the production and distribution of health-conscious, clean-label food products. Their production capabilities, combined with their expertise in delivering high-quality products, make them an ideal partner for Restart Life.

"We are thrilled to have this co-packer as our strategic production partner," said Steve Loutskou, CEO of Restart Life Sciences. "Their established reputation, production facility, and history of success in the health food sector make them the perfect fit for Restart. We look forward to bringing our innovative products to market and addressing the growing demand for health-focused foods."

The co-packers' expertise will ensure that the Brain Balls product line is produced in a facility that meets the highest standards of quality and safety. This partnership also opens up exciting opportunities to further expand distribution to new markets, both in Canada and abroad.

Restart Life's CEO plans to visit the co-packer's facility to engage in further discussions and strengthen the collaboration. This visit is also timed to coincide with the Company's participation in Canada's leading trade show for natural, organic, and wellness consumer packaged goods, where it aims to broaden its network and explore new business opportunities.

Further to its news release dated Feb 7, 2025, Restart Life has closed a debt settlement transaction to settle an aggregate $118,476.75 of debt (the "Debt Settlement"). Pursuant to the Debt Settlement, the Company has allotted and issued 1,579,689 units at a price of $0.075 per unit. Each unit consists of one common share of the company and one transferable share purchase warrant, with each warrant entitling the holder to acquire one additional common share at an exercise price of $0.10 for a period of 12 months from the date of issuance. All securities issued under the Debt Settlement are subject to a hold period of four months and one day, expiring on June 19, 2025.

The Debt Settlement shall constitute a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on the exemptions under section 5.5(a) and section 5.7(1)(a) from the formal valuation and minority shareholder approval requirements of MI 61-101, as the fair market value of the shares issued to the related party does not exceed 25% of the Company's market capitalization, as determined in accordance with MI 61-101.

In addition, the Company has granted an aggregate 1,830,000 incentive stock options ("the Options") and 3,095,000 restricted share units (the "RSUs") to officers, directors and consultants of the Company. The Options and RSUs are valid for a two year term and the Options are exercisable at a price $0.10 per share . The Options and RSUs have been granted under and are governed by the terms of the Company's incentive stock option plan and restricted share unit plan approved by shareholders at the Company's annual general meeting held on February 7, 2025.

Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Sciences' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

On behalf of the board of directors
Chief Executive Officer - Steve Loutskou
Tel: +1 (778) 819-0244
Email: hello@restartlife.co

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241436

FAQ

What is the strategic partnership announced by Restart Life Sciences (NMLSD) in February 2025?

Restart Life Sciences announced a strategic production partnership with a Canadian co-packer to manufacture their Brain Balls product line, handling raw ingredients, packaging, and shipping from their British Columbia facility.

How much debt did Restart Life Sciences (NMLSD) settle in February 2025?

Restart Life Sciences settled $118,476.75 of debt by issuing 1,579,689 units at $0.075 per unit, with each unit including one common share and one warrant exercisable at $0.10.

How many stock options and RSUs did Restart Life Sciences (NMLSD) grant in February 2025?

Restart Life Sciences granted 1,830,000 stock options and 3,095,000 RSUs to officers, directors, and consultants, exercisable at $0.10 per share with a two-year term.

What is the exercise price and expiry period for the warrants issued in NMLSD's February 2025 debt settlement?

The warrants are exercisable at $0.10 per share and expire 12 months from the date of issuance.